ethyl 1-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl}piperidine-4-carboxylate | 648449-93-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: ethyl 1-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl}piperidine-4-carboxylate
• 英文别名: ethyl 1-[6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl]piperidine-4-carboxylate
• CAS: 648449-93-8
• 化学式: C₂₀H₂₀N₄O₄S
• 分子量: 412.469
• InChiKey: MOXJCDYPMNAYNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  127
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  ethyl 1-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl}piperidine-4-carboxylate 在 sodium hydroxide 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 以82%的产率得到1-[6-(2,4-dioxo-1,3-thiazolidin-5-ylidenemethyl)-quinazolin-4-yl]-piperidine-4-carboxylic acid
  参考文献：
  名称：

  [EN] AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES
  [FR] DERIVES DE BENZENE A FUSION AZOLIDINONE-VINYLE

  摘要：

  本发明涉及式(I)的噁唑烷二酮-乙烯融合苯衍生物，用于治疗和/或预防自身免疫性疾病和/或炎症性疾病、心血管疾病、神经退行性疾病、细菌或病毒感染、肾脏疾病、血小板聚集、癌症、移植排斥或肺部损伤。式(I)中，A、X、Y、Z、R1、R2和n如描述中所述。

  公开号：

  WO2004007491A1

文献信息

• Azolidinone-vinyl fused-benzene derivatives
  申请人：Rueckle Thomas

  公开号：US20060122176A1

  公开（公告）日：2006-06-08

  The present invention is related to azolidinedione-vinyl fused-benzene derivatives of formula (I) for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries. Formula (I), wherein A, X, Y, Z, R 1 , R 2 and n are as described in the description.

  本发明涉及公式（I）的噻唑烷二酮-乙烯基融合苯衍生物，用于治疗和/或预防自身免疫性疾病和/或炎症性疾病、心血管疾病、神经退行性疾病、细菌或病毒感染、肾脏疾病、血小板聚集、癌症、移植排斥或肺损伤。公式（I）中，A，X，Y，Z，R1，R2和n如说明书中所述。
• Use of compounds for increasing spermatozoa motility
  申请人：De Luca Giampiero

  公开号：US20050222225A1

  公开（公告）日：2005-10-06

  The invention relates to a process for the improvement of spermatozoa fertilization activity, in particular for the increase of spermatozoa motility, by using a compound of formula (I). The invention further relates to uses and methods of compounds of formula (I) in infertility and assisted reproduction techniques (ART) as well as to a medium for storage and/or transportation of spermatozoa comprising said P13K inhibitors.

  本发明涉及一种使用式(I)化合物改善精子受精活性的方法，特别是增加精子运动性的方法。本发明还涉及式(I)化合物在不孕症和辅助生殖技术（ART）中的用途和方法，以及一种包含所述P13K抑制剂的精子储存和/或运输介质。
• AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES
  申请人：RUECKLE Thomas

  公开号：US20090306069A1

  公开（公告）日：2009-12-10

  The present invention is related to azolidinedione-vinyl fused-benzene derivatives of formula (I) for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries. wherein A, X, Y, Z, R 1 , R 2 and n are as described in the description.

  本发明涉及式（I）的噁唑烷二酮-乙烯基融合苯衍生物，用于治疗和/或预防自身免疫性疾病和/或炎症性疾病、心血管疾病、神经退行性疾病、细菌或病毒感染、肾脏疾病、血小板聚集、癌症、移植排斥或肺损伤。其中A、X、Y、Z、R1、R2和n如描述所述。
• P13K Inhibitors for the Treatment of Endometriosis
  申请人：Palmer Stephen

  公开号：US20080306057A1

  公开（公告）日：2008-12-11

  This invention relates to a method of treating and/or preventing endometriosis comprising administering a PI3K inhibitor. The PI3K inhibitor can also be administered combined with a hormonal suppressor. The invention further relates to the treatment of endometriosis-related infertility.
• P13 kinase gamma inhibitors for the treatment of anaemia
  申请人：Wetzker Reinhard

  公开号：US20090042773A1

  公开（公告）日：2009-02-12

  This present invention is related to the use of selective PD Kinase gamma inhibitors for the manufacture of a medicament for the treatment of disorders related to erythrocyte deficiency. Specifically, the present invention is related to the use of selective PI3 Kinase gamma inhibitors, e.g. substituted azolidinone-vinyl fused-benzene derivatives for the treatment of an anaemia, including haemolytic anaemia, aplastic anaemia and pure red cell anaemia. (I) wherein A, X, Y 1 , Y 2 , Z, n, R 1 and R 2 are described in details in the description hereinafter.